Novo Nordisk's (NVO) third-quarter earnings were solid enough to soothe investor jitters and turn the market's attention toward upcoming trial results for a potentially game-changing new weight-loss ...

Use of the weight loss drug was also linked to shorter hospital stays. Eli Lilly and Novo Nordisk are the main players in the GLP-1 field, but they're facing competition from compounding pharmacies, ...

As we get closer to the end of third-quarter earnings season, this is a good moment to take a snapshot and see which companies have improved their profit margins while also booking large increases in ...

But what makes Altimmune's drug different from existing drugs, and what kind of market opportunity does it have? Altimmune's ...

Susan McGowan, 58, from Lanarkshire, died from multiple organ failure, septic shock and pancreatitis after taking two ...

Even a juggernaut like Eli Lilly ( LLY 2.71%) can miss the mark sometimes. When it reported its third-quarter earnings on Oct. 30, its share price plunged to the tune of 11% before recovering somewhat ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

Ricks is being recognized for his contributions to Indiana’s life sciences sector and his global impact on health care ...

Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the ...

Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide ...

Indianapolis-based pharmaceutical giant Eli Lilly and Company has purchased 30.9 acres of vacant land to the north and to the ...

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” third quarter 2024 investor ...